# Efficacy of Aldosterone Antagonist Therapy for Prevention of New Atrial Fibrillation

> **NCT03929718** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Piedmont Healthcare** · enrollment: 50 (estimated)

## Conditions studied

- AFib

## Interventions

- **DRUG:** Spironolactone
- **DRUG:** No Spironolactone

## Key facts

- **NCT ID:** NCT03929718
- **Lead sponsor:** Piedmont Healthcare
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-04-24
- **Primary completion:** 2025-09
- **Final completion:** 2027-09
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03929718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03929718, "Efficacy of Aldosterone Antagonist Therapy for Prevention of New Atrial Fibrillation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03929718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*